Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment).

摘要: The aim of this study was to investigate the impact midgut versus hindgut as primary tumor site in patients with metastatic colorectal cancer (mCRC) receiving chemotherapy FuFIRI or mIROX. We analyzed 423 from a phase III trial that randomized 1 : fashion either cohort grouped into (n=82) and (n=341) tumors. (midgut vs. hindgut) correlated parameters treatment efficacy survival. Our comprised 82 presenting tumors 341 Tumors origin compared were associated inferior outcome. Objective response rate 37 43% (P=0.34), median progression-free survival 6.0 8.2 months (P=0.024, hazard ratio: 0.75), overall 13.6 21.8 (P=0.001, 0.65). Patients mCRC showed clear trend toward outcome both arms. However, effect appeared less pronounced mIROX arm. Further datasets large trials various regimens are required confirmation.